Clinical differences between botulinum neurotoxin type A and B

Toxicon

Volumn 107, Issue , 2015, Pages 77-84

  Bentivoglio, Anna Rita ^a   Del Grande, Alessandra ^a   Petracca, Martina ^a   Ialongo, Tamara ^a   Ricciardi, Lucia ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Abobotulinum; BoNT A; BoNT B; Botulinum toxin; Incobotulinum; Onabotulinum; Rimabotulinum; Therapy; Treatment

Indexed keywords

BICARBONATE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; NEUTRALIZING ANTIBODY; SYNAPTOBREVIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIGENICITY; ARTICLE; BLEPHAROSPASM; CERVICAL DYSTONIA; CLINICAL PRACTICE; CLOSTRIDIUM BOTULINUM; CLOSTRIDIUM BOTULINUM TYPE A; CLOSTRIDIUM BOTULINUM TYPE B; CLOSTRIDIUM BOTULINUM TYPE C; CLOSTRIDIUM BOTULINUM TYPE D; CLOSTRIDIUM BOTULINUM TYPE E; CLOSTRIDIUM BOTULINUM TYPE F; CLOSTRIDIUM BOTULINUM TYPE G; CLOSTRIDIUM BOTULINUM TYPE H; CONSTIPATION; DISEASE COURSE; DISULFIDE BOND; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DYSPHAGIA; ENZYMATIC DEGRADATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED MEDICINE; HAND DISEASE; HAND DRYNESS; HEMIDIAPHRAGM; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; IMMUNOGENICITY; LD50; NAUSEA; NONHUMAN; PARKINSON DISEASE; PH; PILOT STUDY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; RADIOIMMUNOPRECIPITATION; SPASTICITY; SYNAPTOSOME; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WESTERN BLOTTING; XEROSTOMIA; AUTONOMIC NERVOUS SYSTEM DISEASES; COMPARATIVE STUDY; DRUG EFFECTS; IMMUNOLOGY; SKELETAL MUSCLE; TORTICOLLIS;

AUTONOMIC NERVOUS SYSTEM DISEASES; BOTULINUM TOXINS, TYPE A; HUMANS; MUSCLE, SKELETAL; TORTICOLLIS; TREATMENT OUTCOME;

EID: 84947767013     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2015.08.001     Document Type: Article

References (97)

1. K.R. Aoki, D. Ranoux, and J. Wissel Using translational medicine to understand clinical differences between botulinum toxin formulations Eur. J. Neurol. 13 Suppl. 4 2006 10 19
2. M.Z. Atassi Basic immunological aspects of botulinum toxin therapy Mov. Disord. 19 Suppl. 8 2004 S68 S84
3. M.Z. Atassi Immune recognition of BoNTs A and B: how anti-toxin antibodies that bind to the heavy chain obstruct toxin action Toxicon 54 2009 600 613
4. J.F. Baizabal-Carvallo, J. Jankovic, and E. Pappert Flu-like symptoms following botulinum toxin therapy Toxicon 58 2011 1 7
5. J.R. Barash, and S.S. Arnon A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins J. Infect. Dis. 209 2014 183 191
6. M.P. Barnes, D. Best, L. Kidd, B. Roberts, S. Stark, P. Weeks, and J. Whitaker The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A - initial experiences Eur. J. Neurol. 12 2005 947 955
7. L. Baumann, A. Slezinger, M. Halem, J. Vujevich, K. Mallin, C. Charles, L.K. Martin, L. Black, and J. Bryde Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis Dermatol Surg. 31 2005 263 270
8. L. Baumann, A. Slezinger, M. Halem, J. Vujevich, L.K. Martin, L. Black, and J. Bryde Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis Int. J. Dermatol 44 2005 418 424
9. R. Benecke, W.H. Jost, P. Kanovsky, E. Ruzicka, G. Comes, and S. Grafe A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia Neurology 64 2005 1949 1951
10. A.R. Bentivoglio, A. Fasano, T. Ialongo, F. Soleti, S. Lo Fermo, and A. Albanese Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs Neurotox. Res. 15 2009 224 231
11. A.R. Bentivoglio, A. Fasano, T. Ialongo, and F. Soleti Lo Fermo S, Albanese A outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm Eur. J. Neurol. 16 2009 392 398
12. A.R. Bentivoglio, T. Ialongo, F. Bove, F. De Nigris, and A. Fasano Retrospective evaluation of the dose equivalence of Botox and Dysport in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story Neurol. Sci. 33 2012 261 267
13. B. Berman, L. Seeberger, and R. Kumar Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia Mov. Disord. 20 2005 233 237
14. A. Blitzer Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia Otolaryngol. Head. Neck Surg. 133 2005 836 838
15. G. Borodic, E. Johnson, M. Goodnough, and E. Schantz Botulinum toxin therapy, immunologic resistance, and problems with available materials Neurology 46 1996 26 29
16. A. Brashear, M.F. Lew, D.D. Dykstra, C.L. Comella, S.A. Factor, R.L. Rodnitzky, R. Trosch, C. Singer, M.F. Brin, J.J. Murray, J.D. Wallace, A. Willmer-Hulme, and M. Koller Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia Neurology 53 1999 1439 1446
17. A. Brashear, A.L. McAfee, E.R. Kuhn, and J. Fyffe Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial Arch. Phys. Med. Rehabil. 85 2004 705 709
18. A. Brashear Botulinum toxin type B: a new injectable treatment for cervical dystonia Expert Opin. Investig. Drugs 10 2001 2191 2199
19. M. Brin, J. Charmaine, and J. Maltman Botulinum toxin type A products are not interchangeable: a review of the evidence Biol. Targets Ther. 8 2014 227 241
20. M.F. Brin, C.L. Comella, J. Jankovic, F. Lai, and M. Naumann CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay Mov. Disord. 23 2008 1353 1360
21. M.F. Brin, M.F. Lew, C.H. Adler, C.L. Comella, S.A. Factor, J. Jankovic, C. O'Brien, J.J. Murray, J.D. Wallace, A. Willmer-Hulme, and M. Koller Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia Neurology 53 1999 1431 1438
22. G.S. Burke The occurrence of Bacillus botulinus in nature J. Bacteriol. 4 1919 541 553
23. J.E. Callaway Botulinum toxin type B (Myobloc): pharmacology and biochemistry Clin. Dermatol 22 2004 23 28
24. L. Carli, C. Montecucco, and O. Rossetto Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg Muscle Nerve 40 2009 374 380
25. R.B. Chinnapongse, M.F. Lew, J.J. Ferreira, K.L. Gullo, P.R. Nemeth, and Y. Zhang Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials Clin. Neuropharmacol. 35 2012 215 223
26. C. Colosimo, M. Chianese, M. Giovannelli, M.F. Contarino, and A.R. Bentivoglio Botulinum toxin type B in blepharospasm and hemifacial spasm J. Neurol. Neurosurg. Psychiatry 74 2003 687
27. C. Colosimo, D. Tiple, and A. Berardelli Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review Neurotox. Res. 22 2012 265 273
28. C.L. Comella, J. Jankovic, K.M. Shannon, J. Tsui, M. Swenson, S. Leurgans, and W. Fan Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia Neurology 65 2005 1423 1429
29. C. Cordivari, V.P. Misra, A. Vincent, S. Catania, K.P. Bhatia, and A.J. Lees Secondary non-responsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test Mov. Disord. 21 2006 1737 1741
30. J. Costa, C. Espírito-Santo, A. Borges, J.J. Ferreira, M. Coelho, P. Moore, and C. Sampaio Botulinum toxin type B for cervical dystonia Cochrane Database Syst. Rev. 2005 Jan 25 CD004315
31. W.T. Dauer, R.E. Burke, P. Greene, and S. Fahn Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia Brain 121 1998 547 560
32. A. de Paiva, F.A. Meunier, J. Molg, K.R. Aoki, and J.O. Dolly Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals Proc. Natl. Acad. Sci. U. S. A. 96 1999 3200 3205
33. B.Z. Dolimbek, J. Jankovic, and M.Z. Atassi Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response Immunol. Investig. 31 2002 247 262
34. N. Dover, J.R. Barash, K.K. Hill, G. Xie, and S.S. Arnon Molecular characterization of a novel botulinum neurotoxin type H gene J. Infect. Dis. 209 2014 192 202
35. D. Dressler, and R. Benecke Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis Eur. Neurol. 49 2003 34 38
36. D. Dressler, and H. Bigalke Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure J. Neurol. 252 2005 904 907
37. D. Dressler, and G. Dirnberger Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay Eur. Neurol. 45 2001 257 260
38. D. Dressler, and F.A. Saberi Safety aspects of high-dose Xeomin therapy J. Neurol. 253 Suppl. 2 2006 May II/141-42 ABS-P562
39. D. Dressler Clinical presentation and management of antibody-induced failure of botulinum toxin therapy Mov. Disord. 19 Suppl. 8 2004 S92 S100
40. R. Eleopra, V. Tugnoli, R. Quatrale, O. Rossetto, and C. Montecucco Different types of botulinum toxin in humans Mov. Disord. 19 Suppl. 8 2004 S53 S59
41. A. Esquenazi, A. Albanese, M.B. Chancellor, E. Elovic, K.R. Segal, D.M. Simpson, C.P. Smith, and A.B. Ward Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome Toxicon 67 2013 115 128
42. ®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated J. Neurol. Sci. 346 2014 116 120
43. S.A. Factor, E.S. Molho, S. Evans, and P.J. Feustel Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia Mov. Disord. 20 2005 1152 1160
44. B.R. Frueh, D.P. Felt, T.H. Wojno, and D.C. Musch Treatment of blepharospasm with botulinum toxin. A preliminary report Arch. Ophthalmol. 102 1984 1464 1468
45. D.J. Gelb, D.M. Yoshimura, R.K. Olney, D.H. Lowenstein, and M.J. Aminoff Change in pattern of muscle activity following botulinum toxin injections for torticollis Ann. Neurol. 29 1991 370 376
46. C.E. Gill, N.D. Manus, M.W. Pelster, J.A. Cook, W. Title, A.L. Molinari, and D. Charles Continuation of long-term care for cervical dystonia at an academic movement disorders clinic Toxins (Basel) 5 2013 776 783
47. H. Goschel, K. Wohlfarth, J. Frevert, R. Dengler, and H. Bigalke Botulinum A toxin therapy: neutralizing and non neutralizing antibodies-therapeutic consequences Exp. Neurol. 147 1997 96 102
48. P. Greene, S. Fahn, and B. Diamond Development of resistance to botulinum toxin type A in patients with torticollis Mov. Disord. 9 1994 213 217
49. S. Gu, S. Rumpel, J. Zhou, J. Strotmeier, H. Bigalke, K. Perry, C.B. Shoemaker, A. Rummel, and R. Jin Botulinum neurotoxin is shielded by NTNHA in an interlocked complex Science 335 2012 977 981
50. A. Guidubaldi, A. Fasano, T. Ialongo, C. Piano, M. Pompili, R. Mascianà, L. Siciliani, M. Sabatelli, and A.R. Bentivoglio Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease Mov. Disord. 26 2011 313 319
51. M. Hallett, A. Albanese, D. Dressler, K.R. Segal, D.M. Simpson, D. Truong, and J. Jankovic Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders Toxicon 67 2013 94 114
52. P.A. Hanna, J. Jankovic, and A. Vincent Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies J. Neurol. Neurosurg. Psychiatry 66 1999 612 616
53. P.A. Hanna, and J. Jankovic Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response Neurology 50 1998 1624 1629
54. C.H. Hatheway, and C. Dang Immunogenicity of the neurotoxins of Clostridium botulinum J. Jankovic, M. Hallett, Therapy with Botulinum Toxin 1994 Marcel Dekker New York (NY) 93 107
55. G.Y. Hsiung, S.K. Das, R. Ranawaya, A.L. Lafontaine, and O. Suchowersky Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period Mov. Disord. 17 2002 1288 1293
56. T. Hunt, and K. Clarke Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A Clin. Neuropharmacol. 32 2009 28 31
57. J. Jankovic, and M.F. Brin Therapeutic uses of botulinum toxin N. Engl. J. Med. 324 1991 1186 1194
58. J. Jankovic, C. Hunter, B.Z. Dolimbek, G.S. Dolimbek, C.H. Adler, A. Brashear, C.L. Comella, M. Gordon, D.E. Riley, K. Sethi, C. Singer, M. Stacy, D. Tarsy, and M.Z. Atassi Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia Neurology 67 2006 2233 2235
59. J. Jankovic, and K. Schwartz Response and immunoresistance to botulinum toxin injections Neurology 45 1995 1743 1746
60. J. Jankovic, K.D. Vuong, and J. Ahsan Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia Neurology 60 2003 1186 1188
61. J. Jankovic Botulinum toxin in clinical practice J. Neurol. Neurosurg. Psychiatry 75 2004 951-917
62. E.A. Johnson Validity of botulinum neurotoxin serotype H J. Infect. Dis. 210 2014 992 993
63. S.R. Kalb, J. Baudys, B.H. Raphael, J.K. Dykes, C. Luquez, S.E. Maslanka, and J.R. Barr Functional characterization of botulinum neurotoxin serotype H as a hybrid of known Serotypes F and A (BoNT F/A) Anal. Chem. 87 2015 3911 3917
64. J. Kerner Vergiftung durch verdorbene Würste Tübinger Blätter für Naturwissenschaften Arzneykd. 3 1817 1 25
65. K.R. Kessler, and R. Benecke The EBD test-a clinical test for the detection of antibodies to botulinum toxin type A Mov. Disord. 12 1997 95 99
66. K.R. Kessler, M. Skutta, and R. Benecke Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group J. Neurol. 246 1999 265 274
67. G. Kranz, A. Paul, B. Voller, M. Posch, C. Windischberger, E. Auff, and T. Sycha Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study Br. J. Dermatol 164 2011 176 181
68. G. Kranz, T. Sycha, B. Voller, A. Gleiss, P. Schnider, and E. Auff Pain sensation during intradermal injections of three different botulinum toxin preparations in different doses and dilutions Dermatol Surg. 32 2006 886 890
69. G. Lagalla, M. Millevolte, M. Capecci, L. Provinciali, and M.G. Ceravolo Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study Mov. Disord. 21 2006 704 707
70. O. Lange, H. Bigalke, R. Dengler, F. Wegner, M. deGroot, and K. Wohlfarth Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin. Neuropharmacol. 32 2009 213 218
71. J. Leuchs Beiträge zur Kenntnis des Toxins und Antitoxins des Bacillus botulinus Ztschr Hyg. u Infekt. 65 1920 55 84
72. M.F. Lew, B.T. Adornato, D.D. Duane, D.D. Dykstra, S.A. Factor, J.M. Massey, M.F. Brin, J. Jankovic, R.L. Rodnitzky, C. Singer, M.R. Swenson, D. Tarsy, J.J. Murray, M. Koller, and J.D. Wallace Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia Neurology 49 1997 701 707
73. P.L. Lowe, and N.J. Lowe Botulinum toxin type B: pH change reduces injection pain, retains efficacy Dermatol Surg. 40 2014 1328 1333
74. M. Moers-Carpi, T. Dirschka, G. Feller-Heppt, S. Hilton, K. Hoffmann, W.G. Philipp-Dormston, A. Rütter, K. Tan, M.A. Chapman, and A. Fulford-Smith A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines J. Cosmet. Laser Ther. 14 2012 296 303
75. K. Muller, E. Mix, F. Adib Saberi, D. Dressler, and R. Benecke Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity J. Neural Transm. 116 2009 579 585
76. M. Naumann, L.M. Boo, A.H. Ackerman, and C.J. Gallagher Immunogenicity of botulinum toxins J. Neural Transm. 120 2013 275 290
77. ®) across multiple indications Mov. Disord. 25 2010 2211 2218
78. M. Naumann, D. Dressler, M. Hallett, J. Jankovic, G. Schiavo, K.R. Segal, and D. Truong Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders Toxicon 67 2013 141 152
79. Z. Nüssgens, and P. Roggenkämper Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm Graefes Arch. Clin. Exp. Ophthalmol. 235 1997 197 199
80. W.G. Ondo, C. Hunter, and W. Moore A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease Neurology 62 2004 37 40
81. J. Palace, A. Nairne, N. Hyman, T.V. Doherty, and A. Vincent A radioimmuno-precipitation assay for antibodies to botulinum A Neurology 50 1998 1463 1466
82. E.J. Pappert, and T. Germanson Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, non-inferiority trial Mov. Disord. 23 2008 510 517
83. Petracca, M., Guidubaldi, A., Ricciardi, L., Ialongo, T., Del Grande, A., Mulas, D., Di Stasio, E., Bentivoglio, A.R., Botulinum Toxin A and B in sialorrhea: long-term data and literature overview, Toxicon: This issue.
84. W. Prager, and T. Rappl Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines J. Cosmet. Dermatol 11 2012 267 271
85. J. Ramirez-Castaneda, and J. Jankovic Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up Toxicon 90 2014 344 348
86. P. Roggenkämper, W.H. Jost, K. Bihari, G. Comes, and S. Grafe NT 201 Blepharospasm Study Team. Efficacy and safety of a new Botulinum Toxin type A free of complexing proteins in the treatment of blepharospasm J. Neural Transm. 113 2006 303 312
87. C. Sampaio, J.J. Ferreira, F. Simões, M.J. Rosas, M. Magalhães, A.P. Correia, A. Bastos-Lima, R. Martins, and A. Castro-Caldas DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-Dysport and Botox-assuming a ratio of 4:1 Mov. Disord. 12 1997 1013 1018
88. R. Savica, B.R. Grossardt, J.H. Bower, B.T. Klassen, and J.Y. Matsumoto Clinical failure of botulinum toxin A in movement disorders Park. Relat. Disord. 18 2012 73 75
89. A.B. Scott Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery Ophthalmology 87 1980 1044 1049
90. A.B. Scott Botulinum toxin injection of eye muscles to correct strabismus Trans. Am. Ophthalmol. Soc. 79 1981 734 770
91. R.R. Sloop, B.A. Cole, and R.O. Escutin Human response to botulinum toxin injection: type B compared with type A Neurology 49 1997 189 194
92. R. Tintner, R. Gross, U.F. Winzer, K.A. Smalky, and J. Jankovic Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial Neurology 65 2005 765 767
93. R.M. Trosch, C.H. Adler, and E.J. Pappert Botulinum toxin type B (Myobloc) in subjects with hemifacial spasm: results from an open-label, dose-escalation safety study Mov. Disord. 22 2007 1258 1264
94. D.D. Truong, P.A. Cullis, C.F. O'Brien, M. Koller, T.P. Villegas, and J.D. Wallace BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study) Mov. Disord. 12 1997 772 775
95. J.K. Tsui, M. Hayward, E.K. Mak, and M. Schulzer Botulinum toxin type B in the treatment of cervical dystonia: a pilot study Neurology 45 1995 2109 2110
96. E. van Ermengem Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. E. van Ermengem. Originally published as "Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus" in Zeitschrift für Hygiene und Infektionskrankheiten 26: 1-56, 1897 Rev. Infect. Dis. 1 1979 701 719
97. M. Zuber, M. Sebald, N. Bathien, J. de Recondo, and P. Rondot Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance Neurology 43 1993 1715 1718